{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:22:43Z","timestamp":1787746963769,"version":"build-2784847793"},"reference-count":37,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune checkpoint inhibitor-induced immune thrombocytopenia (ICI-ITP) is a rare but severe adverse event that may lead to bleeding complications and may require therapeutic changes or interventions. The clinical condition and interventions are highly complex; there are certainly tumour-type and combination-therapy differences, as well as individual ICI-agent factors that modify the risk of thrombocytopenia. ICI-ITP shares some common features, even though its pathogenesis differs markedly from that of traditional ITP. However, ICI-ITP is a clinically important complication; a deeper analysis of factors related to ICI\u2013platelet interactions is also necessary. White blood cell\u2013lymphocyte and platelet count ratios may have prognostic value in predicting the development of a low platelet count. Platelet counts themselves might influence the effectiveness of ICI-type anticancer interventions by facilitating T-cell-induced neoexpression of PD-1 on platelet surfaces. Baseline platelet counts and immunoglobulin levels may also modify treatment outcomes. Platelet activation can also promote immune-related adverse events. ICI-induced ITP-like syndrome\u2019s prognostic factors are not only experimental facts but also clinically important. The connections among platelet counts, activation, immunoglobulins, and cell ratios are likely important factors influencing ICI-induced ITP risk reduction and the improvement of tumour-directed immune response by tailoring ICI selection to tumour type and specific baseline cellular characteristics.<\/jats:p>","DOI":"10.3390\/cancers18172773","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:53:42Z","timestamp":1787745222000},"page":"2773","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Checkpoint Inhibitors and Platelets from Treatment-Induced Thrombocytopenia to Complex Immune and Immune-Related Adverse Events"],"prefix":"10.3390","volume":"18","author":[{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"first","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBloodNet (European Reference Network on Rare Haematological Diseases), 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-8200","authenticated-orcid":false,"given":"Mikl\u00f3s","family":"Udvardy","sequence":"additional","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBloodNet (European Reference Network on Rare Haematological Diseases), 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3507-9997","authenticated-orcid":false,"given":"Zs\u00f3fia","family":"Milt\u00e9nyi","sequence":"additional","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBloodNet (European Reference Network on Rare Haematological Diseases), 4032 Debrecen, Hungary"},{"name":"Doctoral School of Clinical Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chen, K., Zhu, F., Li, X., and Yoshimura, T. (2026). Advances in Immune Checkpoint Inhibitors for Cancer Treatment. Cancers, 18.","DOI":"10.3390\/cancers18111804"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Desimpel, P.H., Petit, P.F., Van den Eynde, B.J., and Zhu, J. (2025). Unlocking the mystery of the PD-1\/PD-L1 axis: Beyond the checkpoint hype. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1708873"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-025-01734-x","article-title":"Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025)","volume":"18","author":"Huang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109969","DOI":"10.1016\/j.bioorg.2026.109969","article-title":"A critical review of gold(I) complexes as anticancer agents: From canonical mechanisms to immune activation","volume":"179","author":"Zhang","year":"2026","journal-title":"Bioorg. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hoc.2025.12.005","article-title":"Early-Stage Hodgkin Lymphoma: Time for Novel Agents?","volume":"40","author":"Patel","year":"2026","journal-title":"Hematol. Oncol. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12672-025-04361-7","article-title":"Immune checkpoint blockade in cancer: Current insights and future horizons","volume":"17","author":"Saman","year":"2026","journal-title":"Discov. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Calvo, R. (2019). Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00454"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104976","DOI":"10.1016\/j.critrevonc.2025.104976","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: Current status and future perspectives","volume":"216","author":"Zhang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jtha.2024.12.016","article-title":"Platelets and megakaryocytes in cancer","volume":"23","author":"Josefsson","year":"2025","journal-title":"J. Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/S0049-3848(20)30406-0","article-title":"Coagulation signaling and cancer immunotherapy","volume":"191","author":"Ruf","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10238-025-01688-x","article-title":"Haematological toxicities with immune checkpoint inhibitors in digestive system tumors: A systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Han","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_12","first-page":"e62163","article-title":"The Potential Adverse Impact of Post-Treatment Thrombocytopenia on Clinical Outcomes in Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"16","year":"2024","journal-title":"Cureus"},{"key":"ref_13","first-page":"392","article-title":"Management of Hematologic Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"12","author":"Rogers","year":"2021","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hulsbergen-Veelken, C., Herbschleb, K.H., Verhaar, M.C., Khairoun, M., and Ocak, G. (2025). Hematological ratios, immune-related adverse events and mortality in patients treated with immune checkpoint inhibitors. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0336491"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9935076","DOI":"10.1155\/2021\/9935076","article-title":"Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors","volume":"2021","author":"Bai","year":"2021","journal-title":"J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rivet, V., Sibaud, V., Dion, J., Volosov, T., Biteau, M., Pastissier, A., Delavigne, K., Cougoul, P., Rauzy, O., and Comont, T. (2024). Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: A case report and literature review. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1353896"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1021\/acs.nanolett.8b02321","article-title":"Engineering PD-1-Presenting Platelets for Cancer Immunotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27460","DOI":"10.18632\/oncotarget.25446","article-title":"PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy","volume":"9","author":"Rolfes","year":"2018","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12964-025-02034-0","article-title":"PD-L1 positive platelets mediate resistance to immune checkpoint inhibitors in patients with colorectal cancer","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"152311","DOI":"10.1016\/j.imbio.2022.152311","article-title":"Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation","volume":"228","author":"Cunningham","year":"2023","journal-title":"Immunobiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4251\/wjgo.v16.i3.577","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events","volume":"16","author":"Jiang","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Wang, M., Dong, W., Chen, J., Wu, P., Wang, Y., Zhang, X., Cao, Y., Wang, Z., Zhong, Z., and Zhong, Y. (2026). Platelet-to-lymphocyte ratio for prognostication in immune checkpoint inhibitor-treated cancer patients: A meta-analysis of 13027 patients highlighting nivolumab-responsive renal cell carcinoma. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1732790"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1078155219887212","article-title":"Pembrolizumab-induced thrombotic thrombocytopenic purpura","volume":"26","author":"Dickey","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12967-022-03359-x","article-title":"Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma","volume":"20","author":"Guida","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2025031449","article-title":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors","volume":"147","author":"Leaf","year":"2026","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12957-022-02695-y","article-title":"Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1\/PD-L1 inhibitors: A retrospective analysis","volume":"20","author":"Ma","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S0007-4551(18)30393-X","article-title":"Biomarqueurs pr\u00e9dictifs de r\u00e9ponse aux inhibiteurs de points de contr\u00f4le immuns","volume":"105","author":"Frelau","year":"2018","journal-title":"Bull. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Liu, G., Zhang, S., Mo, Z., Huang, T., Yu, Q., Lu, X., and He, P. (2024). Association of thrombocytopenia with immune checkpoint inhibitors: A large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1407894"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/jjco\/hyac150","article-title":"The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations","volume":"52","author":"Chiang","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"18324","DOI":"10.1038\/s41598-026-46923-x","article-title":"Elevated plasma IgG is associated with improved treatment response and survival in advanced non-small cell lung cancer patients treated with anti-PD-1 therapy","volume":"16","author":"Ohkuma","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Alcar, L., Bauer, D., Pomej, K., Meischl, T., Mandorfer, M., Reiberger, T., Trauner, M., Scheiner, B., and Pinter, M. (2023). Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0282680"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Torii, K., Iizuka, A., Shimizu, D., Nakanishi, K., Tanaka, C., Nakagawa, N., Umeda, S., Sato, Y., Tanaka, H., and Takami, H. (2026). High Serum IgA Identifies Poor Responders to Immune Checkpoint Inhibitors in Patients with Unresectable Esophageal Squamous Cell Carcinoma. Ann. Surg. Oncol., Epub ahead of print.","DOI":"10.1245\/s10434-026-19879-5"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kong, H., Xie, R., and Liu, Z. (2025). Predictive factors and outcomes of immune-related adverse events in Chinese patients treated with immune checkpoint inhibitors: A real-world retrospective study. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1655724"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: A comprehensive review","volume":"101","author":"Ghanem","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e71948","DOI":"10.1002\/cam4.71948","article-title":"Current Knowledge of Immune Checkpoint Inhibitor-Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management","volume":"15","author":"Dai","year":"2026","journal-title":"Cancer Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/JBM.S468921","article-title":"Successful Treatment of Steroid-Refractory Immune Thrombocytopenia in a Patient Developing Multiple Myeloma While on Immune Checkpoint Inhibitor Therapy for Lung Cancer: A Case Report","volume":"15","author":"Hayashi","year":"2024","journal-title":"J. Blood Med."},{"key":"ref_37","first-page":"359","article-title":"Immune Checkpoint Inhibitors and CAR-T Cell Therapy: Thrombotic and vascular complications","volume":"9","author":"Udvardy","year":"2025","journal-title":"Clin. Biomed. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2773\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:57:19Z","timestamp":1787745439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/17\/2773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":37,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18172773"],"URL":"https:\/\/doi.org\/10.3390\/cancers18172773","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}